Adhesive capsulitis, or "frozen shoulder," is a painful condition commonly encountered in outpatient orthopaedic clinics. It has a prevalence of 2% to 5% among outpatients but of about 20% to 30% in patients with diabetes mellitus (DM).^[@bibr21-2325967119859277],[@bibr23-2325967119859277]^ The pathogenesis of this condition remains unclear, although associated factors include female sex, trauma, age over 40 years, DM, prolonged immobilization, thyroid disease, stroke, myocardial infarction, and autoimmune disease.^[@bibr3-2325967119859277]^

Common nonoperative regimens for adhesive capsulitis include supervised neglect with analgesia, supervised physical therapy, an intra-articular corticosteroid injection (IAI), a suprascapular nerve block (SSNB), manual brisement, and saline dilatation.^[@bibr13-2325967119859277],[@bibr15-2325967119859277],[@bibr17-2325967119859277],[@bibr22-2325967119859277]^ No therapeutic intervention is currently universally accepted as most effective for restoring range of motion (ROM) and decreasing pain in patients with this disease.^[@bibr19-2325967119859277]^ It is widely accepted that physical therapy and stretching with use of analgesics are useful in the treatment of adhesive capsulitis, leading to improved joint mobility and the restoration of function.^[@bibr2-2325967119859277],[@bibr17-2325967119859277],[@bibr33-2325967119859277]^ However, these interventions are usually painful, which negatively affects patient compliance during the rehabilitation program. Therefore, an IAI or SSNB may be beneficial before physical therapy.^[@bibr6-2325967119859277],[@bibr27-2325967119859277],[@bibr37-2325967119859277]^ An IAI, one of the most common procedures, can lead to satisfactory results in the treatment of adhesive capsulitis, with improved ROM and prompt pain reduction.^[@bibr3-2325967119859277],[@bibr4-2325967119859277],[@bibr6-2325967119859277],[@bibr15-2325967119859277],[@bibr21-2325967119859277],[@bibr23-2325967119859277],[@bibr30-2325967119859277]^ Previous studies have shown that an SSNB is also safe and effective, with faster and more efficient resolution of pain and restoration of ROM.^[@bibr11-2325967119859277],[@bibr27-2325967119859277],[@bibr37-2325967119859277]^

We assumed that a combination of these 2 safe and effective modalities might be a good treatment option because of its cost-effectiveness and acceptance among patients with adhesive capsulitis. The purpose of our study was to compare the efficacy of combined SSNB and IAI with that of IAI alone in the treatment of adhesive capsulitis. We hypothesized that combined SSNB and IAI will improve pain and function better than IAI alone.

Methods {#section1-2325967119859277}
=======

Patient Selection {#section2-2325967119859277}
-----------------

We performed a retrospective review of 102 consecutive patients diagnosed with adhesive capsulitis who were treated at an outpatient clinic from July 2016 to January 2017. This study was approved by an institutional review board, and the requirement for obtaining informed consent was waived. Among the 102 patients, magnetic resonance imaging (MRI) was performed on 55 (53.9%) patients; 44 patients underwent noncontrast MRI at another hospital, and 11 patients underwent noncontrast MRI at our institute. The inclusion criteria were (1) adhesive capsulitis diagnosed by 2 orthopaedic specialists and (2) a minimum functional and radiological follow-up of 2 months. The exclusion criteria were (1) rheumatoid arthritis, (2) osteoarthritis, (3) postoperative stiff shoulders, (4) sequelae of infection, and (5) partial- or full-thickness rotator cuff tears as confirmed by MRI or ultrasonography.

An SSNB with an IAI (SSNB + IAI) was performed in 48 patients treated between July 2016 and October 2016, whereas an IAI alone was performed in 54 patients treated between November 2016 and January 2017. All patients were assessed before the intervention and at 2 weeks and 2 months after the intervention. Missing subjective outcome data were completed with telephone interviews. Through the telephone calls, follow-up data of more than 1 year (mean, 19 months \[range, 17-23 months\]) for the American Shoulder and Elbow Surgeons (ASES) score, function visual analog scale (FVAS), and pain visual analog scale (PVAS) were available. After the initial intervention, nonsteroidal anti-inflammatory drugs were given in both groups. All patients in both groups underwent a shoulder rehabilitation program consisting of active and passive ROM exercises as well as strengthening exercises of the rotator cuff and scapular stabilizing muscles at the outpatient clinic on the day of the first intervention.

Interventions {#section3-2325967119859277}
-------------

###  {#section4-2325967119859277}

#### Intra-articular Corticosteroid Injection {#section5-2325967119859277}

All injections were performed at the same site using the posterior route under ultrasonographic guidance. Each injection contained 40 mg (1 mL) of triamcinolone acetonide and 4.5 mL of 2% lidocaine. After thorough sterilization, 5 mL of the combined solution was injected from the lateral to medial direction using the in-plane technique to place the tip within the joint capsule. If the patient had a PVAS score of ≥3 at the 2-week assessment, 1 more IAI was performed.

#### SSNB + IAI {#section6-2325967119859277}

An SSNB was conducted using ultrasonography. With the patient seated, the spine of the scapula was identified. A transverse scan of the scapular spine (which could be identified by palpation) was first obtained, followed by a scan of the spinoglenoid notch. Color Doppler sonography might be useful at this stage to identify the suprascapular artery, which usually courses medially to the nerve. From this site, the nerve could then be easily tracked up to the coracoid notch. A needle was positioned at the desired location in the notch around the nerve using an in-plane approach. For this injection, 9.5 mL of 0.5% bupivacaine and 20 mg (0.5 mL) of triamcinolone acetonide were used ([Figure 1](#fig1-2325967119859277){ref-type="fig"}). In the SSNB + IAI group, 20 mg (0.5 mL) of triamcinolone acetonide and 4.5 mL of 2% lidocaine were used for the IAI to match the total amount of corticosteroid (40 mg) used in the IAI group. If the patient had a PVAS score of ≥3 at the 2-week assessment, 1 more IAI was performed.

![Ultrasonographic images of the suprascapular nerve block (SSNB) at the spinoglenoid notch. (A) An ultrasonographic image of the suprascapular nerve. The hyperechoic line (solid arrowheads) is the inferior fascia of the supraspinatus (SSP). The suprascapular artery and nerve are located below this line. (B, C) After locating the suprascapular artery with a Doppler scan, the needle (open arrowheads) is inserted using a medial in-plane approach such that the tip is placed close to the spinoglenoid notch (solid arrows), where the suprascapular neurovascular bundle is located. As the bundle is barely visible, particular caution should be taken when performing this procedure. AC, acromion; G, glenoid. (D) Local anesthetic spreading around the suprascapular nerve after the injection (open arrows).](10.1177_2325967119859277-fig1){#fig1-2325967119859277}

Clinical Evaluation {#section7-2325967119859277}
-------------------

Patients were regularly evaluated in the outpatient clinic. The medical records of all patients were reviewed independently.

Clinical results were assessed using the PVAS, FVAS, ASES score,^[@bibr25-2325967119859277]^ Korean Shoulder Scoring System (KSS),^[@bibr34-2325967119859277]^ Constant score,^[@bibr10-2325967119859277]^ Simple Shoulder Test (SST),^[@bibr18-2325967119859277]^ and Shoulder Pain and Disability Index (SPADI)^[@bibr8-2325967119859277],[@bibr29-2325967119859277]^ before the intervention and at 2 weeks and 2 months after the intervention. ROM, including forward flexion (FF), external rotation (ER) of the side, and abduction of the shoulder (ABD), was measured using a goniometer before the intervention and at each follow-up. ROM of the contralateral shoulder was measured before the intervention to verify the difference between the involved and contralateral sides, thus clarifing the diagnosis. Internal rotation of the back was not measured with goniometry; instead, it was scored from 0 to 14 points for the region from the buttock to T4 along the level of the vertebra. The patients were asked if they had any history of DM, thyroid disease, or trauma, as these are major secondary causes of adhesive capsulitis of the shoulder.

Statistical Analysis {#section8-2325967119859277}
--------------------

Statistical analysis was performed using SAS version 9.4 (SAS Institute). A power analysis revealed that a sample of 51 patients in each group was required to detect a 1-point difference on the FVAS with a power of 80% and an α of 0.05, and a sample of 42 patients in each group was required to detect a 5-point difference on the ASES with a power of 80% and an α of 0.05. In the analysis of differences between the 2 groups, the normality hypothesis was tested with the Shapiro-Wilk test; the Student *t* test and Wilcoxon rank-sum test were then used for parameters following and deviating from the normal distribution, respectively. The chi-square test was used to examine the association between 2 categorical variables in demographic data. In the analysis of changes according to time, all the measurements in both groups had a normal distribution, and the paired *t* test was applied. To control for the duration of symptoms and presence of the DM (the 2 confounding variables that had *P* values \<.2 on the *t* test, Wilcoxon rank-sum test, or chi-square test; *P* = .074 and .110, respectively), a linear regression analysis was used. A *P* value \<.05 was considered to represent a statistically significant difference.

Results {#section9-2325967119859277}
=======

The 102 study patients consisted of 28 men and 74 women with a mean age of 54.17 ± 7.12 years. In the SSNB + IAI group, there were 14 men and 34 women with a mean age of 54.31 ± 6.47 years (range, 42-67 years). Eleven (22.9%), 9 (18.8%), and 8 (16.7%) patients, respectively, named DM, thyroid disease, and trauma as the causative event. The mean duration of symptoms was 7.73 ± 7.59 months (range, 1-48 months), and the dominant shoulder was affected in 26 (54.2%) patients ([Table 1](#table1-2325967119859277){ref-type="table"}).

###### 

Demographic Data of Patients*^a^*

![](10.1177_2325967119859277-table1)

                             SSNB + IAI (n = 48)   IAI (n = 54)   *P*
  -------------------------- --------------------- -------------- ------
  Age, y                     54.31 ± 6.47          54.04 ± 7.71   .847
  Sex                                                             .714
   Male                      14 (29.2)             14 (25.9)      
   Female                    34 (70.8)             40 (74.1)      
  Shoulder                                                        .743
   Left                      26 (54.2)             31 (57.4)      
   Right                     22 (45.8)             23 (42.6)      
  Dominant shoulder          26 (54.2)             28 (51.9)      .815
  Duration of symptoms, mo   7.73 ± 7.59           6.26 ± 7.51    .328
  Diabetes mellitus          11 (22.9)             6 (11.1)       .112
  Thyroid disease            9 (18.8)              14 (25.9)      .389
  Trauma                     8 (16.7)              6 (11.1)       .418

*^a^*Values are presented as mean ± SD or n (%). IAI, intra-articular corticosteroid injection; SSNB, suprascapular nerve block.

In the IAI group, there were 14 men and 40 women with a mean age of 54.04 ± 7.71 years (range, 40-79 years). Six (11.1%), 14 (25.9%), and 6 (11.1%) patients, respectively, had a history of DM, thyroid disease, and trauma. The mean duration of symptoms was 6.26 ± 7.51 months (range, 1-44 months), and the dominant shoulder was affected in 28 (51.9%) patients ([Table 1](#table1-2325967119859277){ref-type="table"}).

No complications occurred in either group. There were no significant differences between the groups in demographics and clinical characteristics before the intervention, except in the FVAS and SPADI scores (*P* \> .05) ([Tables 1](#table1-2325967119859277){ref-type="table"} and [2](#table2-2325967119859277){ref-type="table"}). ROM of the involved shoulder before the intervention was significantly lower compared with that of the contralateral shoulder ([Table 3](#table3-2325967119859277){ref-type="table"}).

###### 

Clinical Characteristics Before Intervention*^a^*

![](10.1177_2325967119859277-table2)

                     SSNB + IAI       IAI              *P* Value
  ------------------ ---------------- ---------------- -----------
  PVAS               6.73 ± 1.33      6.30 ± 1.46      .158
  FVAS               3.75 ± 1.87      4.91 ± 1.40      **.001**
  ASES               31.17 ± 11.01    35.22 ± 11.31    .070
  Constant           35.50 ± 8.81     38.91 ± 10.08    .074
  KSS                40.38 ± 11.55    39.98 ± 10.38    .857
  SST                3.15 ± 1.47      3.26 ± 1.31      .770
  SPADI pain         59.92 ± 14.17    52.28 ± 14.01    **.007**
  SPADI disability   63.44 ± 15.28    57.78 ± 13.38    **.049**
  SPADI total        62.44 ± 14.07    55.61 ± 12.78    **.020**
  FF                 121.46 ± 22.31   126.85 ± 23.05   .181
  ER                 33.33 ± 13.26    35.00 ± 15.14    .617
  IR                 4.67 ± 3.19      5.09 ± 3.67      .479
  ABD                102.50 ± 29.21   112.41 ± 32.44   .090

*^a^*Values are presented as mean ± SD. Bolded *P* values indicate statistically significant between-group differences (*P* \< .05). ABD, abduction; ASES, American Shoulder and Elbow Surgeons; ER, external rotation; FF, forward flexion; FVAS, function visual analog scale; IAI, intra-articular corticosteroid injection; IR, internal rotation; KSS, Korean Shoulder Scoring System; PVAS, pain visual analog scale; SPADI, Shoulder Pain and Disability Index; SSNB, suprascapular nerve block; SST, Simple Shoulder Test.

###### 

ROM Between Involved and Contralateral Shoulders Before Intervention*^a^*

![](10.1177_2325967119859277-table3)

        SSNB + IAI                        IAI                                       
  ----- ---------------- ---------------- -------- ---------------- --------------- --------
  FF    121.46 ± 22.31   159.79 ± 10.20   \<.001   126.85 ± 23.05   163.70 ± 8.96   \<.001
  ER    33.33 ± 13.26    63.12 ± 17.03    \<.001   35.00 ± 15.14    67.22 ± 10.88   \<.001
  IR    4.67 ± 3.19      11.37 ± 1.99     \<.001   5.09 ± 3.67      12.18 ± 1.86    \<.001
  ABD   102.50 ± 29.21   157.50 ± 15.64   \<.001   112.41 ± 32.44   163.33 ± 8.01   \<.001

*^a^*Values are presented as mean ± SD. There were significant differences between the involved and contralateral shoulders on all ROM parameters (*P* \< .05). ABD, abduction; ER, external rotation; FF, forward flexion; IAI, intra-articular corticosteroid injection; IR, internal rotation; ROM, range of motion; SSNB, suprascapular nerve block.

At the 2-week and 2-month assessments, all the follow-up parameters significantly improved in both the SSNB + IAI and the IAI groups ([Tables 4](#table4-2325967119859277){ref-type="table"} and [5](#table5-2325967119859277){ref-type="table"}). There was no significant difference between groups in the number of patients who received an additional IAI during the second week after the intervention (n = 31 \[64.6%\] in SSNB + IAI group vs n = 32 \[59.3%\] in IAI group; *P* = .581) ([Table 6](#table6-2325967119859277){ref-type="table"}). In addition, the ASES, FVAS, and PVAS scores at a minimum of 1-year follow-up (mean, 19 months \[range, 17-23 months\]) were available. The improvements from baseline scores also remained significant at 1-year follow-up among these 3 clinical measures in both groups. However, there were no significant differences in scores between the 2-month and 1-year follow-ups ([Figure 2](#fig2-2325967119859277){ref-type="fig"}).

###### 

Differences in Follow-up Parameters in the SSNB + IAI Group*^a^*

![](10.1177_2325967119859277-table4)

                                      After Intervention                             
  ------------------ ---------------- -------------------- -------- ---------------- --------
  PVAS               6.73 ± 1.33      4.27 ± 1.65          .001     3.25 ± 1.31      \<.001
  FVAS               3.75 ± 1.87      5.73 ± 1.83          \<.001   6.77 ± 1.29      \<.001
  ASES               31.17 ± 11.01    54.06 ± 13.35        \<.001   64.21 ± 11.05    \<.001
  Constant           35.50 ± 8.81     52.04 ± 10.73        \<.001   60.73 ± 10.32    \<.001
  KSS                40.38 ± 11.55    58.46 ± 12.26        .001     66.00 ± 11.22    \<.001
  SST                3.15 ± 1.47      5.44 ± 1.43          .005     6.90 ± 1.29      \<.001
  SPADI pain         59.92 ± 14.17    38.92 ± 14.01        \<.001   31.10 ± 11.24    \<.001
  SPADI disability   63.44 ± 15.28    45.25 ± 13.72        \<.001   35.00 ± 11.63    \<.001
  SPADI total        62.44 ± 14.07    42.83 ± 12.87        \<.001   34.15 ± 11.10    \<.001
  FF                 121.46 ± 22.31   143.13 ± 20.44       \<.001   153.13 ± 17.15   \<.001
  ER                 33.33 ± 13.26    46.46 ± 13.45        .010     54.79 ± 13.84    \<.001
  IR                 4.67 ± 3.19      7.81 ± 3.11          .009     9.02 ± 2.76      .005
  ABD                102.50 ± 29.21   134.79 ± 23.97       \<.001   151.25 ± 20.28   \<.001

*^a^*Values are presented as mean ± SD. All parameters at both follow-up times showed significant improvements compared with before intervention (*P* \< .05). ABD, abduction; ASES, American Shoulder and Elbow Surgeons; ER, external rotation; FF, forward flexion; FVAS, function visual analog scale; IAI, intra-articular corticosteroid injection; IR, internal rotation; KSS, Korean Shoulder Scoring System; PVAS, pain visual analog scale; SPADI, Shoulder Pain and Disability Index; SSNB, suprascapular nerve block; SST, Simple Shoulder Test.

###### 

Differences in Follow-up Parameters in the IAI Group*^a^*

![](10.1177_2325967119859277-table5)

                                      After Intervention                             
  ------------------ ---------------- -------------------- -------- ---------------- --------
  PVAS               6.30 ± 1.46      3.48 ± 1.51          \<.001   2.81 ± 1.29      \<.001
  FVAS               4.91 ± 1.40      6.31 ± 1.49          \<.001   7.13 ± 1.26      \<.001
  ASES               35.22 ± 11.31    57.11 ± 13.19        \<.001   63.76 ± 11.49    \<.001
  Constant           38.91 ± 10.08    53.59 ± 11.59        \<.001   61.09 ± 10.34    \<.001
  KSS                39.98 ± 10.38    58.48 ± 12.61        .009     67.35 ± 1.51     \<.001
  SST                3.26 ± 1.31      5.52 ± 1.59          .010     6.56 ± 1.48      \<.001
  SPADI pain         52.28 ± 14.01    34.52 ± 12.12        \<.001   29.54 ± 10.01    \<.001
  SPADI disability   57.78 ± 13.38    41.26 ± 14.19        \<.001   34.76 ± 12.41    \<.001
  SPADI total        55.61 ± 12.78    38.20 ± 12.30        \<.001   32.44 ± 10.23    \<.001
  FF                 126.85 ± 23.05   142.41 ± 19.32       \<.001   151.48 ± 16.53   \<.001
  ER                 35.00 ± 15.14    47.41 ± 14.94        .029     55.00 ± 12.70    \<.001
  IR                 5.09 ± 3.67      7.80 ± 3.59          .013     9.24 ± 3.35      \<.001
  ABD                112.41 ± 32.44   135.93 ± 29.17       \<.001   148.33 ± 22.04   \<.001

*^a^*Values are presented as mean ± SD. All parameters at both follow-up times showed significant improvements compared with before intervention (*P* \< .05). ABD, abduction; ASES, American Shoulder and Elbow Surgeons; ER, external rotation; FF, forward flexion; FVAS, function visual analog scale; IAI, intra-articular corticosteroid injection; IR, internal rotation; KSS, Korean Shoulder Scoring System; PVAS, pain visual analog scale; SPADI, Shoulder Pain and Disability Index; SST, Simple Shoulder Test.

###### 

Differences in Improvements Between Groups From Before Intervention*^a^*

![](10.1177_2325967119859277-table6)

                          Before Intervention to 2 wk   Before Intervention to 2 mo                                                  
  ----------------------- ----------------------------- ----------------------------- ---------- ----------------- ----------------- ----------
  PVAS                    --2.46 ± 1.38                 --2.81 ± 1.26                 .148       --3.48 ± 1.27     --3.48 ± 1.40     .928
  FVAS                    1.98 ± 1.80                   1.41 ± 1.28                   .076       3.02 ± 1.85       2.22 ± 1.50       **.015**
  ASES                    22.90 ± 11.04                 21.89 ± 10.51                 .636       33.04 ± 10.57     28.54 ± 11.11     **.039**
  Constant                16.54 ± 7.95                  14.69 ± 8.23                  .277       25.23 ± 8.31      22.19 ± 8.22      .060
  KSS                     18.08 ± 10.59                 18.50 ± 8.67                  .696       25.63 ± 10.81     27.37 ± 9.50      .326
  SST                     2.29 ± 1.11                   2.26 ± 1.20                   .928       3.75 ± 0.86       3.30 ± 1.16       **.042**
  SPADI pain              --21.00 ± 13.68               --17.76 ± 11.68               .241       --28.81 ± 14.32   --22.74 ± 12.22   **.029**
  SPADI disability        --18.19 ± 13.54               --16.52 ± 11.31               .578       --28.44 ± 14.18   --23.02 ± 12.51   **.047**
  SPADI total             --19.60 ± 12.72               --17.41 ± 10.74               .412       --28.29 ± 13.53   --23.17 ± 11.61   **.048**
  FF                      21.67 ± 12.77                 15.56 ± 11.92                 **.018**   31.67 ± 14.04     24.63 ± 12.24     **.009**
  ER                      13.13 ± 10.35                 12.41 ± 8.89                  .657       21.46 ± 9.89      20.00 ± 9.71      .377
  IR                      3.15 ± 2.04                   2.70 ± 2.47                   .242       4.35 ± 2.34       4.15 ± 2.57       .568
  ABD                     32.29 ± 18.36                 23.52 ± 22.92                 **.045**   48.75 ± 22.09     35.93 ± 23.59     **.007**
  Additional IAI, n (%)   31 (64.6)                     32 (59.3)                     .581                                           

*^a^*Values are presented as mean ± SD unless otherwise specified. Bolded *P* values indicate statistically significant between-group differences (*P* \< .05). ABD, abduction; ASES, American Shoulder and Elbow Surgeons; ER, external rotation; FF, forward flexion; FVAS, function visual analog scale; IAI, intra-articular corticosteroid injection; IR, internal rotation; KSS, Korean Shoulder Scoring System; PVAS, pain visual analog scale; SPADI, Shoulder Pain and Disability Index; SSNB, suprascapular nerve block; SST, Simple Shoulder Test.

![Clinical outcomes of both groups between before intervention, 2 months, and final follow-up. \*Significant difference (*P* \< .05). ASES, American Shoulder and Elbow Surgeons; FVAS, function visual analog scale; IAI, intra-articular corticosteroid injection; PVAS, pain visual analog scale; SSNB, suprascapular nerve block.](10.1177_2325967119859277-fig2){#fig2-2325967119859277}

A comparison of the groups at the 2-week assessment revealed better FF and ABD values in the SSNB + IAI group (*P* = .018 and *P* = .045, respectively) ([Table 6](#table6-2325967119859277){ref-type="table"}). At the 2-month assessment, the improvements in the FVAS, ASES, SST, and SPADI scores and FF and ABD values were significantly larger in the SSNB + IAI group than in the IAI group ([Table 6](#table6-2325967119859277){ref-type="table"}). Additionally, the improvements in the PVAS, ASES, SST, and SPADI scores between the 2-week and 2-month assessments were significantly better in the SSNB + IAI group ([Table 7](#table7-2325967119859277){ref-type="table"}).

###### 

Differences in Improvements Between Groups From 2-Week to 2-Month Assessments*^a^*

![](10.1177_2325967119859277-table7)

                     SSNB + IAI       IAI             *P* Value
  ------------------ ---------------- --------------- -----------
  PVAS               --1.02 ± 1.00    --0.67 ± 0.75   **.043**
  FVAS               1.04 ± 1.46      0.81 ± 1.10     .286
  ASES               10.15 ± 6.23     6.65 ± 6.18     **.005**
  Constant           8.69 ± 5.36      7.50 ± 4.40     .161
  KSS                7.54 ± 5.05      8.87 ± 5.80     .258
  SST                1.46 ± 0.62      1.04 ± 0.67     **.002**
  SPADI pain         --7.81 ± 7.82    --4.98 ± 5.92   **.037**
  SPADI disability   --10.25 ± 5.65   --6.50 ± 7.11   **.002**
  SPADI total        --8.69 ± 6.42    --5.76 ± 6.58   **.019**
  FF                 10.00 ± 8.25     9.07 ± 8.30     .535
  ER                 8.33 ± 9.07      7.59 ± 6.71     .580
  IR                 1.21 ± 1.47      1.44 ± 1.74     .440
  ABD                16.46 ± 11.76    12.41 ± 15.65   .135

*^a^*Values are presented as mean ± SD. Bolded *P* values indicate statistically significant between-group differences (*P* \< .05). ABD, abduction; ASES, American Shoulder and Elbow Surgeons; ER, external rotation; FF, forward flexion; FVAS, function visual analog scale; IAI, intra-articular corticosteroid injection; IR, internal rotation; KSS, Korean Shoulder Scoring System; PVAS, pain visual analog scale; SPADI, Shoulder Pain and Disability Index; SSNB, suprascapular nerve block; SST, Simple Shoulder Test.

A comparison of the groups at a minimum 1-year follow-up also revealed significantly better ASES and FVAS scores in the SSNB + IAI group. The improvements on the PVAS were larger in the SSNB + IAI group than in the IAI, although this difference was not statistically significant ([Table 8](#table8-2325967119859277){ref-type="table"}).

###### 

Differences in Improvements Between Groups From Before Intervention to Final Follow-up*^a^*

![](10.1177_2325967119859277-table8)

         SSNB + IAI      IAI             *P* Value
  ------ --------------- --------------- -----------
  PVAS   --3.35 ± 1.57   --2.73 ± 1.57   .084
  FVAS   3.27 ± 2.13     1.93 ± 1.56     **.005**
  ASES   35.46 ± 13.86   28.03 ± 12.24   **.015**

*^a^*Values are presented as mean ± SD. Bolded *P* values indicate statistically significant between-group differences (*P* \< .05). ASES, American Shoulder and Elbow Surgeons; FVAS, function visual analog scale; IAI, intra-articular corticosteroid injection; PVAS, pain visual analog scale; SSNB, suprascapular nerve block.

Discussion {#section10-2325967119859277}
==========

In general, the symptoms of adhesive capsulitis, severe pain and limitation of ROM, peak at 3 to 6 months after the onset of this disease.^[@bibr14-2325967119859277],[@bibr17-2325967119859277]^ It is the physician's task to alleviate this flare. Therefore, an early intervention, such as an IAI or SSNB, during this period is crucial and may precede physical therapy to allow patients to fully participate in a rehabilitation program.^[@bibr6-2325967119859277],[@bibr27-2325967119859277],[@bibr37-2325967119859277]^ This study investigated whether the combined effect of an SSNB and IAI improves pain and functional scores during this severe flare phase. Based on our findings, both SSBI + IAI and IAI alone resulted in significantly improved outcome parameters at 2-week and 2-month follow-ups, including pain and functional status. Moreover, at 2-month follow-up, SSBI combined with IAI led to greater improvements in FVAS, ASES, SST, and SPADI scores and FF and ABD values compared with IAI alone, and at 1-year follow-up, FVAS and ASES scores were significantly improved in the SSNB + IAI group compared with the IAI group. However, there were no significant differences between the 2 groups in PVAS, Constant, and KSS scores or in ER and IR at any follow-up time point. Among these parameters, the Constant and KSS scores are similar in that they both include ROM in the score items. According to the results of this study, the combination of an SSNB with an IAI seems to improve function and disability parameters but not ROM, especially in rotations of the shoulder.

Our findings on the use of an IAI for the treatment of adhesive capsulitis are consistent with those in the literature.^[@bibr3-2325967119859277],[@bibr4-2325967119859277],[@bibr6-2325967119859277],[@bibr15-2325967119859277],[@bibr21-2325967119859277],[@bibr23-2325967119859277],[@bibr30-2325967119859277]^ Previous systematic reviews on the use of corticosteroids mostly found evidence of their short-term effectiveness.^[@bibr4-2325967119859277],[@bibr5-2325967119859277],[@bibr24-2325967119859277],[@bibr32-2325967119859277]^ In 2016, Koh^[@bibr21-2325967119859277]^ performed a systematic review of randomized clinical trials on the use of corticosteroid injections in adhesive capsulitis. The authors concluded that a corticosteroid injection is superior to placebo and physical therapy in the short term (up to 12 weeks). Therefore, patients in the early stage of the disease, where the predominant symptom is pain, may consider an early corticosteroid injection, which might help resolve the symptoms quickly, before undergoing physical therapy or performing exercises at home.

Many studies have compared the effectiveness of an SSNB with that of a series of IAIs in the treatment of adhesive capsulitis. Although some concluded that SSNB and IAI had similar efficacy,^[@bibr7-2325967119859277],[@bibr37-2325967119859277]^ others demonstrated that SSNB provided better pain relief and greater functional improvement than IAI.^[@bibr1-2325967119859277],[@bibr13-2325967119859277],[@bibr20-2325967119859277]^

In terms of the effects of SSNB in the treatment of adhesive capsulitis, our study is in agreement with previous studies.^[@bibr11-2325967119859277],[@bibr27-2325967119859277],[@bibr37-2325967119859277]^ Ozkan et al^[@bibr27-2325967119859277]^ compared the effects of SSNB in patients with adhesive capsulitis unresponsive to IAI. In that study, patients' simple pain scores and total pain scores, as well as ABD, ER, and internal rotation values, improved significantly after SSNB. A double-blind randomized clinical trial by Dahan et al^[@bibr11-2325967119859277]^ compared a treatment group that received 10 mL of bupivacaine SSNB with a placebo group that received 10 mL of physiological saline. The authors concluded that the bupivacaine SSNB was effective in reducing pain in adhesive capsulitis at 1 month. In contrast, the present study compared the effectiveness of 2 treatment methods: the combination of SSNB with IAI versus IAI alone. This makes it different from the previous studies.

We performed an additional IAI in patients with a PVAS score of ≥3 at 2-week follow-up. A systematic review of randomized trials using multiple corticosteroid injections in adhesive capsulitis^[@bibr32-2325967119859277]^ suggested that multiple injections are beneficial until 16 weeks from the date of the first injection. Up to 3 injections were beneficial, and there was limited evidence that 4 to 6 injections also had a positive effect. There was no evidence to support more than 6 injections.

We used a common combination of 9.5 mL of 0.5% bupivacaine and 0.5 mL (20 mg) of triamcinolone acetonide for the SSNB in this study. Bupivacaine is the first choice for regional anesthesia owing to its effectiveness, long duration, and milder motor blockade. In addition, some studies have suggested that a combination of corticosteroids with local anesthetics prolongs the efficacy of nerve blockage up to 1.5 to 2 times and decreases pain scores.^[@bibr28-2325967119859277],[@bibr39-2325967119859277]^ Therefore, a combination with a corticosteroid was selected in this study to prolong the blockage duration and increase the analgesic effects. Although bupivacaine is the most widely used long-acting local anesthetic agent, it is associated with various central nervous system and cardiac toxicities.^[@bibr9-2325967119859277],[@bibr26-2325967119859277],[@bibr35-2325967119859277]^ Ropivacaine has been proposed as a promising drug with fewer cardiovascular and central nervous system toxicity effects compared with bupivacaine.^[@bibr31-2325967119859277]^ However, comparative studies of cardiovascular safety have reported that these 2 anesthetic agents have similar efficacy and incidences of cardiotoxicity.^[@bibr16-2325967119859277],[@bibr38-2325967119859277]^ There were no cardiovascular adverse effects in our study.

Our study has several limitations. First, although a sample of 51 patients in each group was required according to the power analysis, loss to follow-up reduced the size of our SSNB + IAI group to 48 patients. Nevertheless, a sample of 42 patients in each group was fulfilled in the case of the ASES score. Second, our study showed significantly lower preintervention SPADI and FVAS scores in the SSNB + IAI group than in the IAI group. This may be because of the inherent weakness of a retrospective cohort study. However, the SSNB + IAI group showed significantly better improvements in the SPADI and FVAS scores than the IAI group at 2-month follow-up, despite the initially inferior clinical scores. This strongly emphasizes the efficacy of the SSNB in our study. Third, 2-month follow-up may be considered to be short. Although a minimum 1-year follow-up was available for ASES, PVAS, and FVAS scores, the final follow-up rate of telephone interviews was 80%. An analysis of a longer follow-up period with the rest of the outcome measures might be beneficial. However, the main question of the present study was whether the 2 procedures had immediate effects on pain and function to facilitate further rehabilitation. Furthermore, it is unclear whether a longer follow-up than 1 year would be informative considering the natural history of this disease. In our study, the ASES, FVAS, and PVAS did not show statistically significant improvements at final follow-up compared with 2 months.

A fourth limitation was that at both 2-month and final follow-up, each group met the minimal clinically important difference (MCID) compared with before the intervention; however, the MCID between the groups might not be fulfilled. The MCID has been reported to be around a 12- to 17-point change on the ASES score after conservative treatment for tendinitis or rotator cuff tears,^[@bibr36-2325967119859277]^ and others have reported that the MCID after treating chronic shoulder pain was a reduction of approximately 2 points on an 11-point numerical pain rating scale.^[@bibr12-2325967119859277]^ However, to our knowledge, there is no previous literature on the MCID of the ASES score or FVAS after conservative treatment for adhesive capsulitis. Fifth, it was difficult to conclude that the SSNB + IAI group had significantly improved outcomes versus the IAI group at final follow-up because of the less than 100% follow-up rate, even after the telephone survey. Sixth, we did not have a control or SSNB-only group. Performing an IAI after an SSNB only took an additional 5 minutes, even with ultrasonographic guidance in our study; hence, we performed an IAI in all cases. Further study would be beneficial to compare the effectiveness between SSNB-only, IAI-only, and SSNB + IAI. Seventh, MRI, which might have been helpful to exclude other comorbidities that may affect the clinical results, was not performed on all patients. However, a thorough ultrasonographic examination was performed in all patients to locate other possible shoulder lesions such as rotator cuff tears. In addition, relatively expensive MRI was not easy to perform routinely on a cost-sensitive outpatient basis. Finally, it was uncertain whether the patients of both groups underwent additional professional rehabilitation. A frozen shoulder is an easily overlooked condition in South Korea, so patients usually do not receive consistent and professional physical therapy outside of a university hospital. Therefore, we assume that the rate of postintervention rehabilitation was not very different between the groups.

Conclusion {#section11-2325967119859277}
==========

Both SSNB + IAI and IAI alone significantly improved pain and functional outcomes in patients with adhesive capsulitis. Moreover, the application of an SSNB with IAI further increased the efficacy, as per the FVAS, ASES, SST, and SPADI scores and FF and ABD values. Furthermore, SSNB + IAI treatment led to greater improvements in FVAS and ASES scores compared with IAI alone at a minimum of 1 year after the intervention. Therefore, an SSNB with an IAI may be a better choice for the treatment of adhesive capsulitis accompanied with severe pain and functional loss.
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